Analyst Tara Bancroft from TD Cowen maintained a Buy rating on Day One Biopharmaceuticals and decreased the price target to $24.00 from $34.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tara Bancroft has given his Buy rating due to a combination of factors related to Day One Biopharmaceuticals’ updated financial outlook and valuation. He incorporates the company’s preliminary fourth-quarter product revenue of $53 million into his model, aligning his forecast with the newly reported figures. In addition, he revises his 2026 sales projection for Ojemda to $240 million, positioning it within the company’s guidance range of $225–250 million, which supports the credibility of the revenue trajectory. These updates feed into a refreshed discounted cash flow analysis that yields a $24 price target.
Despite lowering the target price from $34 to $24, Bancroft continues to see the stock as attractively valued relative to its long-term cash flow potential, underpinning his continued Buy recommendation. The maintained rating suggests confidence that the current share price does not fully reflect the company’s commercial prospects for Ojemda and broader growth profile. Overall, the combination of solid reported revenue, guidance-consistent forward estimates, and supportive valuation work drives his positive stance on Day One Biopharmaceuticals.
In another report released on January 23, JonesTrading also assigned a Buy rating to the stock with a $20.00 price target.